The Eurasian Journal of Medicine
Case Report

Sulfasalazine-Induced Interstitial Fibrosis

Eurasian J Med 2018; 50: 207-209
DOI: 10.5152/eurasianjmed.2018.17302
Read: 2978 Downloads: 722 Published: 03 September 2019


Sulfasalazine has been used in the treatment of inflammatory bowel disease for over 60 years. Although the drug is frequently associated with gastrointestinal adverse effects, pulmonary adverse effects are very rare. Herein, we report a case of interstitial fibrosis resulting from 4-month sulfasalazine therapy for ulcerative colitis in a patient under long-term follow-up in our clinic due to chronic obstructive pulmonary disease.


Cite this article as: Kerget B, Araz O, Yilmazel Ucar E, Aydın O, Akgun M, Saglam L. Sulfasalazine-induced interstitial fibrosis: Case Series of Three Patients. Eurasian J Med 2018; 50(3): 207-209.

EISSN 1308-8742